Clinical studies have demonstrated that daily consumption of Naticol® collagen peptides can help prevent and address common musculoskeletal disorders associated with ageing, including osteoporosis and sarcopenia.
Osteoporosis is a loss of bone mass and deterioration of bone tissue, which results in an increased risk of suffering a fracture. Sarcopenia is a loss of muscle mass and is considered to be a major factor in the reduction of mobility among older people.
Age-related loss of collagen protein in the body’s movement and weight-bearing structures – the joints – aggravates both osteoporosis and sarcopenia.
Supplementation with Naticol® collagen peptides helps to maintain joint mobility naturally, mitigating the impact of musculoskeletal conditions such as these.
Osteoarthritis is an important cause of disability, affecting more than half of the people aged 65 years or older. It is the most prevalent joint disease. To date, the only available treatments aim at reducing symptoms as pain and inflammation, and at maintaining joint mobility.
Intake of 10g of Naticol® collagen peptides on a daily basis up to 12 weeks, clinically demonstrated alleviation of osteoarthritis symptoms.